Company profile
Lupin Limited
LUPIN · NSE (Lupin's current FY2026 results identify Lupin Limited as BSE 500257 / NSE LUPIN, and its official Ranluspec release confirms the product relationship. Sources: https://www.lupin.com/media/press-releases/lupin-fy-2026-and-q4-fy-2026-results ; https://www.lupin.com/media/press-releases/lupin-receives-approval-from-u-s-fda-for-ranluspec-tm-ranibizumab-injection Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Lupin Limited are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Ranibizumab(Lucentis) | Approved | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.